Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$1.43 -1.4%	$1.60	$1.13 ▼ $2.66	$129.39M	2.61	223,863 shs	117,039 shs
ENLV Enlivex Therapeutics	$1.82 +2.2%	$1.25	$0.81 ▼ $2.10	$42.10M	0.8	444,911 shs	2.24 million shs
MCRB Seres Therapeutics	$16.69 -1.0%	$11.91	$6.53 ▼ $26.40	$147.60M	2.9	134,532 shs	55,391 shs
PLX Protalix BioTherapeutics	$1.48 -2.6%	$1.49	$0.89 ▼ $3.10	$117.82M	-0.21	846,234 shs	702,056 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	-1.38%	-4.67%	-9.49%	+2.88%	-18.29%
ENLV Enlivex Therapeutics	+2.25%	+27.27%	+47.97%	+82.00%	+45.60%
MCRB Seres Therapeutics	-1.01%	+17.45%	+19.47%	+123.73%	-7.60%
PLX Protalix BioTherapeutics	-2.63%	-3.90%	+3.50%	-11.38%	+59.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEN Compugen	1.9776 of 5 stars	3.5	3.0	0.0	2.6	0.0	0.0
ENLV Enlivex Therapeutics	3.3352 of 5 stars	3.7	5.0	0.0	3.0	0.8	0.6
MCRB Seres Therapeutics	3.2338 of 5 stars	2.9	1.0	4.6	2.7	0.8	0.0
PLX Protalix BioTherapeutics	3.3915 of 5 stars	3.5	2.0	0.0	3.3	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$4.00	179.72% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	449.45% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	341.38% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	913.51% Upside

Current Analyst Ratings Breakdown

Latest ENLV, CGEN, PLX, and MCRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$27.86M	4.58	N/A	N/A	$0.56 per share	2.55
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
MCRB Seres Therapeutics	$126.32M	1.16	N/A	N/A	$3.76 per share	4.44
PLX Protalix BioTherapeutics	$59.76M	1.97	$0.08 per share	17.80	$0.47 per share	3.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	-$14.23M	-$0.22	N/A	N/A	N/A	-87.45%	-34.77%	-16.82%	N/A
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-350.16%	-67.69%	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.77	N/A	-21.03%	-30.89%	-11.74%	N/A

Latest ENLV, CGEN, PLX, and MCRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	CGEN Compugen	-$0.07	-$0.08	-$0.01	-$0.08	$3.95 million	$1.26 million
8/6/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	-$2.27	+$0.45	-$2.27	$11.75 million	N/A
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	-$0.08	-$0.02	-$0.08	$3.70 million	$2.28 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	4.74	4.74
ENLV Enlivex Therapeutics	N/A	7.20	7.20
MCRB Seres Therapeutics	N/A	1.57	1.57
PLX Protalix BioTherapeutics	N/A	1.98	1.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
ENLV Enlivex Therapeutics	1.02%
MCRB Seres Therapeutics	59.34%
PLX Protalix BioTherapeutics	16.53%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
ENLV Enlivex Therapeutics	12.28%
MCRB Seres Therapeutics	4.70%
PLX Protalix BioTherapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
MCRB Seres Therapeutics	330	8.75 million	8.34 million	Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable

ENLV, CGEN, PLX, and MCRB Headlines

Recent News About These Companies

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2025 Earnings Call Transcript

August 15 at 9:12 AM | insidermonkey.com

Protalix BioTherapeutics Reports Strong Q2 2025 Results

August 15 at 5:43 AM | msn.com

Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

August 14 at 7:43 PM | finanznachrichten.de

Protalix BioTherapeutics, Inc. (NYSE:PLX) Director Aharon Schwartz Acquires 129,000 Shares

August 14 at 5:38 PM | marketbeat.com

Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript

August 14 at 1:06 PM | seekingalpha.com

Protalix BioTherapeutics lifts revenue on strong Elfabrio demand

August 14 at 8:39 AM | proactiveinvestors.com

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

August 14 at 7:01 AM | prnewswire.com

Protalix BioTherapeutics, Inc. (NYSE:PLX) Director Aharon Schwartz Buys 129,000 Shares

August 13 at 5:41 AM | insidertrades.com

Head-To-Head Analysis: Protalix BioTherapeutics (NYSE:PLX) & AlloVir (NASDAQ:ALVR)

August 10, 2025 | americanbankingnews.com

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

August 7, 2025 | prnewswire.com

Protalix Lawsuit Dismissed After Bylaws Amendment

August 1, 2025 | tipranks.com

Protalix BioTherapeutics Names Gilad Mamlok Chief Financial Officer

July 21, 2025 | marketwatch.com

Protalix BioTherapeutics Names SVP and CFO

July 21, 2025 | contractpharma.comC

Protalix Biotherapeutics Inc.: Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

July 21, 2025 | finanznachrichten.de

Protalix BioTherapeutics welcomes new finance chief

July 21, 2025 | proactiveinvestors.com

PLX | Protalix BioTherapeutics Inc. Annual Cash Flow Statement ...

July 10, 2025 | marketwatch.com

Protalix BioTherapeutics joins Russell 3000 and 2000 indexes following annual reconstitution

June 30, 2025 | proactiveinvestors.com

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 14, 2025 | finance.yahoo.com

PLX: First Quarter Results

May 13, 2025 | msn.com

Earnings call transcript: Protalix Q1 2025 results miss forecasts, stock plunges

May 10, 2025 | uk.investing.com

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, CGEN, PLX, and MCRB Company Descriptions

Compugen NASDAQ:CGEN

$1.43 -0.02 (-1.38%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.44 +0.01 (+0.98%)

As of 08/15/2025 07:48 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Enlivex Therapeutics NASDAQ:ENLV

$1.82 +0.04 (+2.25%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.93 +0.11 (+6.04%)

As of 08/15/2025 07:58 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Seres Therapeutics NASDAQ:MCRB

$16.69 -0.17 (-1.01%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$16.28 -0.41 (-2.46%)

As of 08/15/2025 07:58 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Protalix BioTherapeutics NYSE:PLX

$1.48 -0.04 (-2.63%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.50 +0.02 (+1.35%)

As of 08/15/2025 05:27 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time